The impact of antiphospholipid antibodies in Takayasu arteritis
Turkish Journal of Medical Sciences · 01.01.2023 · 53 (1) · 199-205
DOI: 10.55730/1300-0144.5573 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 01.01.2023. Verfasst von Esra Fırat Şentürk und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey. Hauptthemen laut MEDLINE: Takayasu Arteritis, Antiphospholipid Syndrome. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background/aim: The significance of antiphospholipid antibodies (aPL) is controversial in Takayasu arteritis (TA). This study was conducted to explore the frequency of aPL and their association with disease-related complications in TA. Materials and methods: This cross-sectional study was conducted to investigate the presence of anti-cardiolipin (aCL), anti-beta 2 glycoprotein- 1(aß2G1) antibodies, and lupus anticoagulant (LA) in TA patients. TA patients admitted to the Department of Rheumatology of Hacettepe University Faculty of Medicine between December 2015 and September 2016 who fulfilled the American College of Rheumatology (ACR) classification criteria for TA were consecutively enrolled in the study. Patients were grouped according to aPL positivity and compared in terms of disease manifestations, type of vascular involvement at diagnosis, and vascular complications/interventions attributable to TA.
Results
Fifty-three TA (49 female) patients were enrolled in the study. We detected 9 (16.9%) patients with IgM and/or IgG aß2G1 and/or LA positivity. There were no patients with positive aCL. All aß2G1 titers were low. There were no differences in terms of symptoms, signs, type of vascular involvement, the number of patients with disease-related complications or vascular interventions/surgery between aPL (+) and aPL(-) groups (p > 0.05 for all). The number of patients with thrombotic lesions was similar between the groups (p > 0.05). There were no patients with a history of venous thrombosis or on anticoagulant treatment in the aPL(+) group. Only 1 patient with IgM aß2G1 (+) had a history of pregnancy loss.
Conclusion
Our results indicate that aPL positivity is not rare in TA. On the other hand, all aPL titers were low and no differences were found in the frequency of disease-related complications between aPL(+) and aPL(-) patient groups. Only TA patients with atypical manifestations with high suspicion of aPL-related complications should be considered to be investigated for aPL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Hacettepe University, Ankara, Turkey.
Zitieren
APA
Şentürk, E. F., Erden, A., Sarı, A., Armağan, B., Kılıç, L., Kalyoncu, U., Karadağ, Ö., Bilgen, Ş. Ş. A., Kiraz, S., Ertenli, A. İ., & Akdoğan, A. (2023). The impact of antiphospholipid antibodies in Takayasu arteritis. Turkish Journal of Medical Sciences, 53(1), 199-205. https://doi.org/10.55730/1300-0144.5573
Vancouver
Şentürk EF, Erden A, Sarı A, Armağan B, Kılıç L, Kalyoncu U, et al. The impact of antiphospholipid antibodies in Takayasu arteritis. Turkish Journal of Medical Sciences. 2023;53(1):199-205. doi:10.55730/1300-0144.5573
BibTeX
@article{entrk2023,
author = {Şentürk, Esra Fırat and Erden, Abdulsamet and Sarı, Alper and Armağan, Berkan and Kılıç, Levent and Kalyoncu, Umut and Karadağ, Ömer and Bilgen, Şaziye Şule Apraş and Kiraz, Sedat and Ertenli, Ali İhsan and Akdoğan, Ali},
title = {The impact of antiphospholipid antibodies in Takayasu arteritis},
journal = {Turkish Journal of Medical Sciences},
year = {2023},
volume = {53},
number = {1},
pages = {199--205},
doi = {10.55730/1300-0144.5573}
}
EUVIMED